Rosuvastatin ameliorates cognitive impairment in rats fed with high-salt and cholesterol diet via inhibiting acetylcholinesterase activity and amyloid beta peptide aggregation

Human and Experimental Toxicology

Volumn 37, Issue 4, 2018, Pages 399-411

  Husain, I ^a   Akhtar, M ^a   Abdin, M Zainul ^b   Islamuddin, M ^b   Shaharyar, M ^a   Najmi, A K ^a  

^a HAMDARD UNIVERSITY   (India)

^b HAMDARD UNIVERSITY   (India)

Author keywords

acetylcholinesterase enzyme; amyloid beta peptide; Cognitive impairment; high salt and cholesterol diet

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CHOLESTEROL; PIRACETAM; ROSUVASTATIN; ACHE PROTEIN, RAT; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); CHOLINESTERASE INHIBITOR; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; PEPTIDE FRAGMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BIOCHEMICAL ANALYSIS; BRAIN CORTEX; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL INTAKE; COGNITIVE DEFECT; COMPUTER ANALYSIS; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HIPPOCAMPUS; HISTOPATHOLOGY; IN VIVO STUDY; MOLECULAR DOCKING; NEUROBEHAVIORAL ACTIVITY TEST; NONHUMAN; OPEN FIELD TEST; PRIORITY JOURNAL; PROTEIN AGGREGATION; RAT; SALT INTAKE; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; BRAIN; CHEMISTRY; COGNITION; DISEASE MODEL; DRUG EFFECT; ENZYMOLOGY; LOCOMOTION; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN CONFORMATION; PROTEINOSIS; PSYCHOLOGY; STRUCTURE ACTIVITY RELATION; WISTAR RAT;

ACETYLCHOLINESTERASE; AMYLOID BETA-PEPTIDES; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CEREBRAL CORTEX; CHOLESTEROL, DIETARY; CHOLINESTERASE INHIBITORS; COGNITION; COGNITIVE DYSFUNCTION; DISEASE MODELS, ANIMAL; FEMALE; GPI-LINKED PROTEINS; HIPPOCAMPUS; LOCOMOTION; MOLECULAR DOCKING SIMULATION; PEPTIDE FRAGMENTS; PROTEIN AGGREGATION, PATHOLOGICAL; PROTEIN CONFORMATION; RATS, WISTAR; ROSUVASTATIN CALCIUM; SODIUM CHLORIDE, DIETARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 85041090941     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327117705431     Document Type: Article

References (63)

1. Billings LM, Oddo S, Green KN. Intraneuronal Aβ causes the onset of early Alzheimer’s disease-related cognitive deficits in transgenic mice. Neuron 2005; 45: 675–688.
2. Sperling RA, Aisen PS, Beckett LA. Toward defining the preclinical stages of alzheimer’s disease: recommendations from the national institute on aging-alzheimer’s association workgroups on diagnostic guidelines for alzheimer’s disease. Alzheimer’s Demen 2011; 7: 280–292.
3. Bloem B, Poorthuis RB, Mansvelder HD. Cholinergic modulation of the medial prefrontal cortex: the role of nicotinic receptors in attention and regulation of neuronal activity. Front Neural Circuit 2014; 8: 17.
4. Gamba P, Testa G, Gargiulo S. Oxidized cholesterol as the driving force behind the development of Alzheimer’s disease. Front Aging Neurosci 2015; 7: 119.
5. Verri M, Pastoris O, Dossena M. Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer’s disease. Int J Immunopathol Pharmacol 2012; 25: 345–353.
6. Klafki H-W, Staufenbiel M, Kornhuber J. Therapeutic approaches to Alzheimer’s disease. Brain 2006; 129: 2840–2855.
7. Zhou X, Li Y, Shi X. An overview on therapeutics attenuating amyloid β level in Alzheimer’s disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res 2016; 8: 246.
8. Pistell PJ, Morrison CD, Gupta S. Cognitive impairment following high fat diet consumption is associated with brain inflammation. J Neuroimmunol 2010; 219: 25–32.
9. Mogi M, Tsukuda K, Li J-M. Inhibition of cognitive decline in mice fed a high-salt and cholesterol diet by the angiotensin receptor blocker, olmesartan. Neuropharmacology 2007; 53: 899–905.
10. Aggarwal BB. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Ann Rev Nutr 2010; 30: 173.
11. Tang L-Q, Wei W, Chen L-M. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J Ethnopharmacol 2006; 108: 109–115.
12. Wang Y, Chen X. How much of racial/ethnic disparities in dietary intakes, exercise, and weight status can be explained by nutrition-and health-related psychosocial factors and socioeconomic status among US adults? J Am Diet Assoc 2011; 111: 1904–1911.
13. Can ÖD, Ulupinar E, Özkay ÜD. The effect of simvastatin treatment on behavioral parameters, cognitive performance, and hippocampal morphology in rats fed a standard or a high-fat diet. Behav Pharmacol 2012; 23: 582–592.
14. Alvarez EO, Beauquis J, Revsin Y. Cognitive dysfunction and hippocampal changes in experimental type 1 diabetes. Behav Brain Res 2009; 198: 224–230.
15. Taylor F, Huffman MD, Macedo AF. Statins for the primary prevention of cardiovascular disease. The Cochrane Library 2013; 1: CD004816.
16. Haag MD, Hofman A, Koudstaal PJ. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 2009; 80: 13–17.
17. Mihaylova B, Emberson J, Blackwell L. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380: 581–590.
18. Liao JK, Laufs U. Pleiotropic effects of statins. Ann Rev Pharmacol Toxicol 2005; 45: 89.
19. Barone E, Di Domenico F, Butterfield DA. Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 2014; 88: 605–616.
20. da Costa RF, Freire VN, Bezerra EM. Explaining statin inhibition effectiveness of HMG-CoA reductase by quantum biochemistry computations. Phys Chem Chem Phy 2012; 14: 1389–1398.
21. Kata D, Földesi I, Feher L. Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells. Neuroscience 2016; 314: 47–63.
22. Canevari L, Clark JB. Alzheimer’s disease and cholesterol: the fat connection. Neurochem Res 2007; 32: 739–750.
23. Famer D, Wahlund L-O, Crisby M. Rosuvastatin reduces microglia in the brain of wild type and ApoE knockout mice on a high cholesterol diet; implications for prevention of stroke and AD. Biochem Biophys Res Commun 2010; 402: 367–372.
24. Barone E, Cenini G, Di Domenico F. Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action. Pharmacol Res 2011; 63: 172–180.
25. Ghaisas MM, Dandawate PR, Zawar SA. Antioxidant, antinociceptive and anti-inflammatory activities of atorvastatin and rosuvastatin in various experimental models. Inflammopharmacology 2010; 18: 169–177.
26. Hsieh M-T, Tsai F-H, Lin Y-C. Effects of ferulic acid on the impairment of inhibitory avoidance performance in rats. Planta Med 2002; 68: 754–756.
27. Liu RY, Gu R, Qi XL. Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide (1–42) and fed a high-cholesterol diet. J Neurosci Res 2008; 86: 183–193.
28. Duan S, Guan X, Lin R. Silibinin inhibits acetylcholinesterase activity and amyloid β peptide aggregation: a dual-target drug for the treatment of Alzheimer’s disease. Neurobiol Aging 2015; 36: 1792–1807.
29. Rizvi SMD, Shaikh S, Naaz D. Kinetics and molecular docking study of an anti-diabetic drug glimepiride as acetylcholinesterase inhibitor: implication for alzheimer’s disease-diabetes dual therapy. Neurochem Res 2016; 41: 1475–1482.
30. Noolvi MN, Patel HM, Kaur M. Benzothiazoles: search for anticancer agents. Eur J Med Chem 2012; 54: 447–462.
31. Akhtar M, Imam SS, Afroz Ahmad M. Neuroprotective study of Nigella sativa-loaded oral provesicular lipid formulation: in vitro and ex vivo study. Drug Delivery 2014; 21: 487–494.
32. Ansari JA, Bhandari U, Haque S. Enhancement of antioxidant defense mechanism by pitavastatin and rosuvastatin on obesity-induced oxidative stress in Wistar rats. Toxicol Mech Meth 2012; 22: 67–73.
33. Piao Y, Liu Y, Xie X. Change trends of organ weight background data in sprague dawley rats at different ages. J Toxicol Pathol 2013; 26: 29.
34. Kumar P, Bhandari U. Protective effect of trigonella foenum-graecum linn. on monosodium glutamate-induced dyslipidemia and oxidative stress in rats. Indian J Pharmacol 2013; 45: 136.
35. Khan A, Vaibhav K, Javed H. Attenuation of Aβ-induced neurotoxicity by thymoquinone via inhibition of mitochondrial dysfunction and oxidative stress. Mol Cell Biochem 2012; 369: 55–65.
36. Ellman GL, Courtney KD, Andres V. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95.
37. Wang J, Dickson DW, Trojanowski JQ. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer’s disease from normal and pathologic aging. Exp Neurol 1999; 158: 328–337.
38. Thenmozhi AJ, Raja TRW, Janakiraman U. Neuroprotective effect of hesperidin on aluminium chloride induced Alzheimer’s disease in Wistar rats. Neurochem Res 2015; 40: 767–776.
39. Zhang X, Dong F, Ren J. High dietary fat induces NADPH oxidase-associated oxidative stress and inflammation in rat cerebral cortex. Exp Neurol 2005; 191: 318–325.
40. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer’s amyloid β-peptide. Nat Rev Mol Cell Biol 2007; 8: 101–112.
41. Agis-Torres A, Sollhuber M, Fernandez M. Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer’s disease. Curr Neuropharmacol 2014; 12: 2–36.
42. Verhoeff NPL. Acetylcholinergic neurotransmission and the β-amyloid cascade: implications for Alzheimer’s disease. Expert Rev Neurother 2005; 5: 277–284.
43. Iulita MF, Allard S, Richter L. Intracellular Aβ pathology and early cognitive impairments in a transgenic rat overexpressing human amyloid precursor protein: a multidimensional study. Acta Neuropathologica Commun 2014; 2: 1.
44. Laursen B, Mørk A, Plath N. Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice. Behav Brain Res 2013; 240: 146–152.
45. Silva D, Chioua M, Samadi A. Synthesis, pharmacological assessment, and molecular modeling of acetylcholinesterase/butyrylcholinesterase inhibitors: effect against amyloid-β-Induced neurotoxicity. ACS Chem Neurosci 2013; 4: 547–565.
46. Sheng R, Xu Y, Hu C. Design, synthesis and AChE inhibitory activity of indanone and aurone derivatives. Eur J Med Chem 2009; 44: 7–17.
47. Wanamaker BL, Swiger KJ, Blumenthal RS. Cholesterol, statins, and dementia: what the cardiologist should know. Clin Cardiol 2015; 38: 243–250.
48. Morris MC, Tangney CC. Dietary fat composition and dementia risk. Neurobiol Aging 2014; 35: S59–S64.
49. Farr SA, Yamada KA, Butterfield DA. Obesity and hypertriglyceridemia produce cognitive impairment. Endocrinology 2008; 149: 2628–2636.
50. Naderali EK, Ratcliffe SH, Dale MC. Review: obesity and Alzheimer’s disease: a link between body weight and cognitive function in old age. Am J Alzheimer’s Dis Other Demen 2009; 24: 445–449.
51. Di Scala C, Chahinian H, Yahi N. Interaction of alzheimer’s β-amyloid peptides with cholesterol: mechanistic insights into amyloid pore formation. Biochemistry 2014; 53: 4489–4502.
52. Bonarek M, Barberger-Gateau P, Letenneur L. Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 2000; 19: 141–148.
53. Solomon A, Kivipelto M, Wolozin B. Midlife serum cholesterol and increased risk of Alzheimer’s and vascular dementia three decades later. Dement Geriatr Cogn Disord 2009; 28: 75–80.
54. Rajanikant G, Zemke D, Kassab M. The therapeutic potential of statins in neurological disorders. Curr Med Chem 2007; 14: 103–112.
55. Malfitano AM, Marasco G, Proto MC. Statins in neurological disorders: an overview and update. Pharmacol Res 2014; 88: 74–83.
56. Kohsaka A, Laposky AD, Ramsey KM. High-fat diet disrupts behavioral and molecular circadian rhythms in mice. Cell Metab 2007; 6: 414–421.
57. Akhtar M, Maikiyo AM, Khanam R. Ameliorating effects of two extracts of Nigella sativa in middle cerebral artery occluded rat. J Pharm Bioall Sci 2012; 4: 70.
58. Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharm Exp Ther 2003; 306: 821–827.
59. Auld DS, Kornecook TJ, Bastianetto S. Alzheimer’s disease and the basal forebrain cholinergic system: relations to β-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol 2002; 68: 209–245.
60. Bayer TA, Wirths O. Intracellular accumulation of amyloid-Beta-a predictor for synaptic dysfunction and neuron loss in Alzheimer’s disease. Front Aging Neurosci 2010; 2: 8.
61. Pathan AR, Viswanad B, Sonkusare SK. Chronic administration of pioglitazone attenuates intracerebroventricular streptozotocin induced-memory impairment in rats. Life Sci 2006; 79: 2209–2216.
62. Hegazy A, Azeem AA, Shahy E. Comparative study of cholinergic and oxidative stress biomarkers in brains of diabetic and hypercholesterolemic rats. Hum Exp Toxicol 2015; 35: 251–258. 0960327115583361.
63. Zhang L, Dasuri K, Fernandez-Kim S-O. Prolonged diet induced obesity has minimal effects towards brain pathology in mouse model of cerebral amyloid angiopathy: Implications for studying obesity–brain interactions in mice. Biochimica et Biophysica Acta (BBA)-Mol Basis Dis 2013; 1832: 1456–1462.